These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28860080)

  • 1. Rituximab desensitization in three patients with severe rituximab allergy.
    Öztürk E; Özyiğit LP; Öztürk AB; Akay MO; Çetiner M; Ferhanoğlu B
    Curr Probl Cancer; 2017; 41(5):349-354. PubMed ID: 28860080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.
    Wong JT; Long A
    J Allergy Clin Immunol Pract; 2017; 5(6):1564-1571. PubMed ID: 29122155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience.
    Görgülü B; Seval GC; Kendirlinan R; Toprak SK; Özcan M; Bavbek S
    J Investig Allergol Clin Immunol; 2019; 29(6):468-470. PubMed ID: 31530515
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.
    Lebel E; Ben-Yehuda D; Bohbot E; Dranitzki Z; Shalit M; Tal Y
    J Allergy Clin Immunol Pract; 2016; 4(5):1000-2. PubMed ID: 27329468
    [No Abstract]   [Full Text] [Related]  

  • 5. Desensitization to rituximab in a multidisciplinary setting.
    Amorós-Reboredo P; Sánchez-López J; Bastida-Fernández C; do Pazo-Oubiña F; Borràs-Maixenchs N; Giné E; Valero A; Creus-Baró N
    Int J Clin Pharm; 2015 Oct; 37(5):744-8. PubMed ID: 25999014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
    Shikdar S; Totton D; Turco T; Rachshtut M
    Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis.
    V Villarreal-González R; E de Lira-Quezada C; N González-Díaz S; L Carrasco-Díaz L; González-Llano O
    J Oncol Pharm Pract; 2021 Apr; 27(3):747-750. PubMed ID: 32787558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid desensitization of hypersensitivity reactions to chemotherapy agents.
    Castells M
    Curr Drug Saf; 2006 Aug; 1(3):243-51. PubMed ID: 18690934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.
    V Villarreal-Gonzalez R; N Gonzalez-Diaz S; E de Lira-Quezada C; Gómez-Almaguer D; Gómez-De León A; Acuña-Ortega N
    J Oncol Pharm Pract; 2021 Mar; 27(2):505-508. PubMed ID: 32686619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
    Grisariu S; Vaxman I; Gatt M; Elias S; Avni B; Arad A; Pasvolsky O; Raanani P; Paltiel O
    Hematol Oncol; 2017 Dec; 35(4):591-598. PubMed ID: 27734521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
    Brennan PJ; Rodriguez Bouza T; Hsu FI; Sloane DE; Castells MC
    J Allergy Clin Immunol; 2009 Dec; 124(6):1259-66. PubMed ID: 19910036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
    Castells MC; Tennant NM; Sloane DE; Hsu FI; Barrett NA; Hong DI; Laidlaw TM; Legere HJ; Nallamshetty SN; Palis RI; Rao JJ; Berlin ST; Campos SM; Matulonis UA
    J Allergy Clin Immunol; 2008 Sep; 122(3):574-80. PubMed ID: 18502492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Castleman's disease: Rapid desensitization for hypersensitivity reaction to rituximab].
    Boin C; Lambert S; Thomann P; Aujoulat O; Kieffer P
    Rev Med Interne; 2016 Jun; 37(6):433-6. PubMed ID: 26415921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol.
    Pérez-Rodríguez E; Martínez-Tadeo JA; Pérez-Rodríguez N; Hernández-Santana G; Callero-Viera A; Rodríguez-Plata E; García-Robaina JC
    J Allergy Clin Immunol Pract; 2018; 6(5):1621-1627.e6. PubMed ID: 29361511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
    D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
    Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitization protocol for rituximab-induced serum sickness.
    Fajt ML; Petrov AA
    Curr Drug Saf; 2014; 9(3):240-2. PubMed ID: 24861993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
    Sacchi S; Federico M; Vitolo U; Boccomini C; Vallisa D; Baldini L; Petrini M; Rupoli S; Di Raimondo F; Merli F; Liso V; Tabilio A; Saglio G; Vinci G; Brugiatelli M; Dastoli G;
    Haematologica; 2001 Sep; 86(9):951-8. PubMed ID: 11532623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Desensibilización a Rituximab en paciente con proteinuria persistente secundaria a LES].
    Servín-Suárez N; Méndez-Gómez A; Korkowski-Uviña K; Carrillo-Murillo H; Torres-Rojo E; Ortega-Cisneros M; Ochoa-García IV
    Rev Alerg Mex; 2023 Sep; 70(4):. PubMed ID: 37933938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.